Does n-glycosylation-mutated HCV envelope glycoprotein complex enhance antigen-presenting activity and cellular and neutralizing antibody responses?
As our knowledge this is the first study revealing that the naturally poor immunogenicity of E1E2 can be enhanced by the deletion of N-glycans combined with the addition of immune activator CpG by DNA vaccination.
Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with  microalbuminuria.